Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-09-30

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

NCT00419471

Depressive Disorder Coronary Disease

COMPLETED PHASE4

A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

NCT01870843

Depressive Disorder, Major

COMPLETED PHASE4

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

NCT00183677

Depression

COMPLETED PHASE4

Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD

NCT00785434

Major Depressive Disorder

COMPLETED PHASE4

An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms

NCT01814098

Depressive Disorder, Major

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile.

Statistical analysis will be exploratory and mainly descriptive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depression Generalized Anxiety Disorder Panic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Give informed consent
* Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder
* Aged 21 years old and above
* Able to comprehend and comply with protocol
* Not pregnant and if of child-bearing age, using adequate methods of contraception

Exclusion Criteria

* Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs
* Contraindications to escitalopram
* Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease
* History of non-response to escitalopram
* Meets IDF definition of metabolic syndrome
* Significant risk of suicide
* Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No